Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells

Alyssa A. Sprouse, Brittney Shea Herbert

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Resveratrol (RES) inhibits cell growth, induces apoptosis and augments chemotherapeutics in multiple cancer types, although its effects on drug-resistant cancer cells are unknown. Materials and Methods: To study the effects of resveratrol in triple-negative breast cancer cells that are resistant to the common cancer drug, paclitaxel, a novel paclitaxel-resistant cell line was generated from the MDA-MB-231 cell line. Results: The resistant MDA-MB-231/PacR cells exhibited a 12-fold increased resistance to paclitaxel. RES treatment reduced cell proliferation and colony formation and increased senescence and apoptosis in both parental and resistant cells. Importantly, RES augmented the effects of paclitaxel in both cell lines. Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells. Conclusion: RES, both alone and in combination with paclitaxel, may be useful in the treatment of paclitaxel-sensitive and paclitaxel-resistant triple-negative breast cancer cells.

Original languageEnglish (US)
Pages (from-to)5363-5374
Number of pages12
JournalAnticancer Research
Volume34
Issue number10
StatePublished - Oct 1 2014

Fingerprint

Paclitaxel
Breast Neoplasms
Triple Negative Breast Neoplasms
Cell Line
Apoptosis
Neoplasms
resveratrol
Pharmaceutical Preparations
Up-Regulation
Cell Proliferation
Growth
Genes

Keywords

  • Breast cancer
  • Paclitaxel resistance
  • Resveratrol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. / Sprouse, Alyssa A.; Herbert, Brittney Shea.

In: Anticancer Research, Vol. 34, No. 10, 01.10.2014, p. 5363-5374.

Research output: Contribution to journalArticle

@article{574bcb5bd55f4766a3ddf8126fa8835e,
title = "Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells",
abstract = "Background: Resveratrol (RES) inhibits cell growth, induces apoptosis and augments chemotherapeutics in multiple cancer types, although its effects on drug-resistant cancer cells are unknown. Materials and Methods: To study the effects of resveratrol in triple-negative breast cancer cells that are resistant to the common cancer drug, paclitaxel, a novel paclitaxel-resistant cell line was generated from the MDA-MB-231 cell line. Results: The resistant MDA-MB-231/PacR cells exhibited a 12-fold increased resistance to paclitaxel. RES treatment reduced cell proliferation and colony formation and increased senescence and apoptosis in both parental and resistant cells. Importantly, RES augmented the effects of paclitaxel in both cell lines. Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells. Conclusion: RES, both alone and in combination with paclitaxel, may be useful in the treatment of paclitaxel-sensitive and paclitaxel-resistant triple-negative breast cancer cells.",
keywords = "Breast cancer, Paclitaxel resistance, Resveratrol",
author = "Sprouse, {Alyssa A.} and Herbert, {Brittney Shea}",
year = "2014",
month = "10",
day = "1",
language = "English (US)",
volume = "34",
pages = "5363--5374",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells

AU - Sprouse, Alyssa A.

AU - Herbert, Brittney Shea

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Background: Resveratrol (RES) inhibits cell growth, induces apoptosis and augments chemotherapeutics in multiple cancer types, although its effects on drug-resistant cancer cells are unknown. Materials and Methods: To study the effects of resveratrol in triple-negative breast cancer cells that are resistant to the common cancer drug, paclitaxel, a novel paclitaxel-resistant cell line was generated from the MDA-MB-231 cell line. Results: The resistant MDA-MB-231/PacR cells exhibited a 12-fold increased resistance to paclitaxel. RES treatment reduced cell proliferation and colony formation and increased senescence and apoptosis in both parental and resistant cells. Importantly, RES augmented the effects of paclitaxel in both cell lines. Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells. Conclusion: RES, both alone and in combination with paclitaxel, may be useful in the treatment of paclitaxel-sensitive and paclitaxel-resistant triple-negative breast cancer cells.

AB - Background: Resveratrol (RES) inhibits cell growth, induces apoptosis and augments chemotherapeutics in multiple cancer types, although its effects on drug-resistant cancer cells are unknown. Materials and Methods: To study the effects of resveratrol in triple-negative breast cancer cells that are resistant to the common cancer drug, paclitaxel, a novel paclitaxel-resistant cell line was generated from the MDA-MB-231 cell line. Results: The resistant MDA-MB-231/PacR cells exhibited a 12-fold increased resistance to paclitaxel. RES treatment reduced cell proliferation and colony formation and increased senescence and apoptosis in both parental and resistant cells. Importantly, RES augmented the effects of paclitaxel in both cell lines. Up-regulation of the MDR1 and CYP2C8 genes were shown to be potential mechanisms of paclitaxel resistance in the resistant cells. Conclusion: RES, both alone and in combination with paclitaxel, may be useful in the treatment of paclitaxel-sensitive and paclitaxel-resistant triple-negative breast cancer cells.

KW - Breast cancer

KW - Paclitaxel resistance

KW - Resveratrol

UR - http://www.scopus.com/inward/record.url?scp=84917744524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917744524&partnerID=8YFLogxK

M3 - Article

C2 - 25275030

AN - SCOPUS:84917744524

VL - 34

SP - 5363

EP - 5374

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -